GM3 ganglioside: A novel target for the therapy against melanoma

Biotecnologia Aplicada

Volumn 26, Issue 3, 2009, Pages 256-259

  Mazorra, Zaima ^a   Mesa, Cirse ^a   Fernández, Luis E ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CANCER VACCINE; GAMMA INTERFERON; GANGLIOSIDE GM3; IMMUNOGLOBULIN G ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; MELANOMA; MEMBRANE VESICLE; MOUSE; NONHUMAN; PROTEOLIPOSOME; SURVIVAL TIME; TUMOR IMMUNITY; VERY SMALL SIZED PROTEOLIPOSOME;

MURINAE; MUS;

EID: 79551599576     PISSN: 08644551     EISSN: 10272852     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Koon HB, Atkins MB. Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance. Expert Rev Anticancer Ther 2007;7:79-88.
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-915. (Pubitemid 39273730)
3. Kananath D, Hill AD, Djikstra B, Kenelly R, McDermott EM, O'Higgins NJ. Adjuvant therapies in the treatment of stage II and III malignant melanoma. Surgeon 2005;3:245-56.
4. Kudo D, Rayman P, Horton C, et al. Gangliosides expressed by the renal cell carcinoma cell line KK-RC-45 are involved in tumor-induced apoptosis of T cells. Cancer Res 2003;63:1676-83.
5. Dohi T, Nores G, Hakomori S. An IgG3 monoclonal antibody established after immunization with GM3 lactone: immunochemical specificity and inhibition of melanoma cell growth in vitro and in vivo. Cancer Res 1988;48:5680-5.
6. Carr A, Mazorra Z, Alonso DF, et al. A purified GM3 ganglioside conjugated vaccine induces speciWc, adjuvant-dependent and non-transient antitumor activity against B16 mouse melanoma in vitro and in vivo. Melanoma Res 2001;11:219-27.
7. Livingston PO, Ragupati G. Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 1997;45:10-9.
8. Estévez F, Carr A, Solorzano L, et al. Enhancement of the immune response to poorly immunogenic gangliosides after incorporation into very small size proteoliposomes (VSSP).Vaccine 2000;18:190-7 (Pubitemid 29432152)
9. Ravindranath MH, Brazeau SM, Morton DL. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside. Experientia 1994;50:648-53.
10. Ragupathi G, Liu NX, Musselli C, Powell S, Lloyd K, Livingston PO. Antibodies against tumor cell glycolipids and proteins, but not mucins, mediate complement-dependent cytotoxicity. J Immunol 2005;174:5706-12.
11. Lizee G, Radvanyi LG, Overwijk WW, Hwu P. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin Cancer Res 2006;12:2359s-65s.
12. Winter H, Hu HM, McClain K, Urba WJ, Fox BA. Immunotherapy of melanoma: a dichotomy in the requirement for IFN g in vaccine-induced antitumor immunity versus adoptive immunotherapy. J Immunol 2000;166:7370-80.
13. Kiessling R,Wasserman K, Horiguchi S. Tumor induced immune dysfunction. Cancer Immunol Immunother 1999;48:353-62.
14. Barbieri C, Fujisawa MM, Yasuda CL, et al. Effect of surgical treatment on the cellular immune response of gastric cancer patients. Braz J Med Biol Res 2003;36:339-45. (Pubitemid 36442983)
15. Ross MI. Early-stage melanoma: staging criteria and prognostic modeling. Clin Cancer Res 2006;12:312-9.